Scholl Athlete's Foot Powder

Section 4.2:
Wording replaced with posology breakdown (adults & paediatric populations).
Method of administration expanded.

Section 4.3:
"Not recommended for" nail or scalp infections replaced by "Contraindicated in"

Section 4.4:
Addition of "If irritation or rash occurs, use of the the product should be discontinued and medical advice should be sought"

Section 4.6:
Addition of the below in "Pregnancy":
No effects during pregnancy are anticipated since systemic exposure to Tolnaftate is negligible.  Tolnaftate can be used during pregnancy.
Addition of "Breast-feeding" and "Fertility" information

Section 4.7:
"None stated" replaced with "This medication has no known effects on the ability to drive and use machines"

Section 4.8
Addition of MEDdra table.
Addition of "Reporting of Suspected Adverse Reactions" information

Section 4.9:
"Not relevant to topical use" replaced with:
Symptoms: There have been no reports of over dosage with the use of this product.
Management: In the case of over dosage, treatment should be symptomatic and supportive

Section 5.1:
Pharmaceutical group: Tolnaftate, replaced with:
Pharmacotherapeutic group: Dermatological, Antifungals for Dermatological use, Antifungals for Topical use other Antifungals for Topical use. 
Addition of the below sentence in Mechanism of Action paragraph:
"It is a thiocarbamate derivative that inhibits sterol synthesis at the level of squalene epoxidase in the growing of cells"

Section 5.3:
"Not Applicalbe" replaced with "There are no preclinical safety data of relevant to the consumer"

Section 4.2:
Wording replaced with posology breakdown (adults & paediatric populations).
Method of administration expanded.

Section 4.3:
"Not recommended for" nail or scalp infections replaced by "Contraindicated in"

Section 4.4:
Addition of "If irritation or rash occurs, use of the the product should be discontinued and medical advice should be sought"

Section 4.6:
Addition of the below in "Pregnancy":
No effects during pregnancy are anticipated since systemic exposure to Tolnaftate is negligible.  Tolnaftate can be used during pregnancy.
Addition of "Breast-feeding" and "Fertility" information

Section 4.7:
"None stated" replaced with "This medication has no known effects on the ability to drive and use machines"

Section 4.8
Addition of MEDdra table.
Addition of "Reporting of Suspected Adverse Reactions" information

Section 4.9:
"Not relevant to topical use" replaced with:
Symptoms: There have been no reports of over dosage with the use of this product.
Management: In the case of over dosage, treatment should be symptomatic and supportive

Section 5.1:
Pharmaceutical group: Tolnaftate, replaced with:
Pharmacotherapeutic group: Dermatological, Antifungals for Dermatological use, Antifungals for Topical use other Antifungals for Topical use. 
Addition of the below sentence in Mechanism of Action paragraph:
"It is a thiocarbamate derivative that inhibits sterol synthesis at the level of squalene epoxidase in the growing of cells"

Section 5.3:
"Not Applicalbe" replaced with "There are no preclinical safety data of relevant to the consumer"

None provided

None provided